HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Feb.2)- Update on CR Sanjiu's Acquisition of Tasly, China Biotech's Outlook

China Healthcare Weekly (Feb.9) - Vesync Is a High-Quality Company, VBP to Cover Retail Pharmacies

Shanghai Henlius Biotech (2696 HK) - LVC Increased Its Holding of Henlius Again

Shanghai Henlius Biotech (2696 HK)- These Are the Reasons Why LVC May Vote Against the Privatization

Shanghai Henlius Biotech (2696 HK) - About the Deal Break and the Valuation Outlook

Shanghai Henlius Biotech Privatization (2696.HK) - The Offer Price Is Disappointing

China TCM (570.HK) - About the Profit Warning and the Valuation Outlook

Equity Bottom-Up

Shanghai Henlius Biotech  / Equity Bottom-Up

<ul>
<li>There have been quite a few M&amp;As in the field of TCM, with a clear trend of SOEs taking over TCM enterprises due to strategically significant and advantageous integration.</li>
<li>Whether a drug can be approved does not depend on whether it has entered Phase II/III trials. The areas with clearly unmet medical needs often indicate good investment opportunities.</li>
<li>The privatization of Henlius failed. Lin Lijun's dissenting vote was based on a deliberate decision. We are optimistic about the outlook of Henlius due to its strong fundamentals and internationalization. </li>
</ul>


There have been quite a few M&amp;As in the field of TCM, with a clear trend of SOEs taking over TCM enterprises due to strategically significant and advantageous integration.
Whether a drug can be approved does not depend on whether it has entered Phase II/III trials. The areas with clearly unmet medical needs often indicate good investment opportunities.
The privatization of Henlius failed. Lin Lijun's dissenting vote was based on a deliberate decision. We are optimistic about the outlook of Henlius due to its strong fundamentals and internationalization. 


China Resources Sanjiu Medical & Pharma (000999 CH)

中国ヘルスケアウィークリー（1月26日） - ヘンリウスの民営化とTCMのM&amp;Aの失敗から学ぶ重要な教訓

Shanghai Henlius Biotech

中国ヘルスケアウィークリー（1月26日） - ヘンリウスの民営化とTCMのM&amp;Aの失敗から学ぶ重要な教訓

中国ヘルスケアウィークリー（1月26日） - ヘンリウスの民営化とTCMのM&Aの失敗から学ぶ重要な教訓